Alberto Bardelli
机构: University of Torino and IFOM ETS
每年引用次数
引用次数
引用: 76,178
H-指数: 113
I10-指数 : 275
出版物: 567
Amplification of the MET receptor to drive resistance to anti-EGFR therapies in colorectal cancer.
Alberto Bardelli , Simona Corso , Andrea Bertotti , Sebastijan Hobor
Journal of Clinical Oncology 31 11005 -11005
3
2013
Liquid Biopsies: Genotyping Circulating Tumor DNA
Luis A. Diaz , Alberto Bardelli
Journal of Clinical Oncology 32 ( 6) 579 -586
2,075
2014
The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients.
Sara Lonardi , Clara Montagut , Filippo Pietrantonio , Elena Elez
Journal of Clinical Oncology 38
3
2020
TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma
Lipika Goyal , Lei Shi , Leah Y Liu , Ferran Fece de la Cruz
Cancer Discovery 9 ( 8) 1064 -1079
80
2019
EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer
Vito Amodio , Rona Yaeger , Pamela Arcella , Carlotta Cancelliere
Cancer Discovery 10 ( 8) 1129 -1139
32
2020
TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors
Moshe Elkabets , Elisa de Stanchina , Chandra S. Verma , Andrea Ventura
Cancer Discovery 11 ( 1) 126 -141
5
2021
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.
Lipika Goyal , Supriya K. Saha , Leah Y. Liu , Giulia Siravegna
Cancer Discovery 7 ( 3) 252 -263
370
2017
Tumor Evolution as a Therapeutic Target.
Nabil Amirouchene-Angelozzi , Charles Swanton , Alberto Bardelli
Cancer Discovery 7 ( 8) 805 -817
101
2017
The Clinical Impact of the Genomic Landscape of Mismatch Repair–Deficient Cancers
Giovanni Germano , Nabil Amirouchene-Angelozzi , Giuseppe Rospo , Alberto Bardelli
Cancer Discovery 8 ( 12) 1518 -1528
33
2018
The road to resistance: EGFR mutation and cetuximab
Alberto Bardelli , Pasi A Jänne
Nature Medicine 18 ( 2) 199 -200
52
2012
Toward understanding and exploiting tumor heterogeneity
Ash A Alizadeh , Victoria Aranda , Alberto Bardelli , Cedric Blanpain
Nature Medicine 21 ( 8) 846 -853
663
2015
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
Giulia Siravegna , Benedetta Mussolin , Michela Buscarino , Giorgio Corti
Nature Medicine 21 ( 7) 795 -801
977
2015
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
Aaron N Hata , Matthew J Niederst , Hannah L Archibald , Maria Gomez-Caraballo
Nature Medicine 22 ( 3) 262 -269
480
2016
The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death
Chiara Pozzi , Alessandro Cuomo , Ilaria Spadoni , Elena Magni
Nature Medicine 22 ( 6) 624 -631
113
2016
KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy.
Emanuele Valtorta , Sandra Misale , Andrea Sartore-Bianchi , Iris D. Nagtegaal
International Journal of Cancer 133 ( 5) 1259 -1265
215
2013
Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies.
Mariangela Russo , Simona Lamba , Annalisa Lorenzato , Alberto Sogari
Nature Communications 9 ( 1) 2287 -2287
11
2018
A Peptide Representing the Carboxyl-terminal Tail of the Met Receptor Inhibits Kinase Activity and Invasive Growth
Alberto Bardelli , Paola Longati , Tracy A. Williams , Silvia Benvenuti
Journal of Biological Chemistry 274 ( 41) 29274 -29281
70
1999
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad , Chong Sun , Sidong Huang , Federica Di Nicolantonio
Nature 483 ( 7387) 100 -103
1,985
2012
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Sandra Misale , Rona Yaeger , Sebastijan Hobor , Elisa Scala
Nature 486 ( 7404) 532 -536
1,847
2012
HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer
Andrea Sartore‐Bianchi , Alessio Amatu , Luca Porcu , Silvia Ghezzi
Oncologist 24 ( 10) 1395 -1402
83
2019